2025
Treatment outcomes of successful M1 versus M2 thrombectomy for low-ASPECTS stroke patients.
Chen H, Colasurdo M, Matsukawa H, Cunningham C, Maier I, Jabbour P, Kim J, Wolfe S, Rai A, Starke R, Psychogios M, Shaban A, Goyal N, Yoshimura S, Cuellar H, Howard B, Alawieh A, Alaraj A, Ezzeldin M, Romano D, Tanweer O, Mascitelli J, Fragata I, Polifka A, Siddiqui F, Osbun J, Crosa R, Grandhi R, Matouk C, Park M, Levitt M, Brinjikji W, Moss M, Daglioglu E, Williamson R, Navia P, Chowdhry S, Altschul D, Spiotta A, Kan P. Treatment outcomes of successful M1 versus M2 thrombectomy for low-ASPECTS stroke patients. Interventional Neuroradiology 2025, 15910199251343283. PMID: 40530425, PMCID: PMC12176791, DOI: 10.1177/15910199251343283.Peer-Reviewed Original ResearchLow Alberta Stroke Program Early CT ScoreAlberta Stroke Program Early CT ScoreEffect of endovascular thrombectomyM2 occlusionsIntracranial hemorrhageM2 patientsAssociated with intracranial hemorrhageOdds of all-cause mortalityMulticenter retrospective studyOdds of poor outcomeMultivariate logistic regression modelAll-cause mortalityMiddle cerebral arteryStroke patientsM1 patientsM1 occlusionCT scoreRetrospective studyLogistic regression modelsPoor outcomeMultivariable adjustmentPrimary outcomeCerebral arteryTreatment outcomesEndovascular thrombectomySafety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Nassar A, Alaiwi S, Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman R, Johnson D, Grynberg S, Shapira R, Kwan J, Woodford R, Long G, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang E, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Herrera M, Foderaro S, Nana F, Kim C, Sackstein P, Parikh K, Desai A, Smith C, Cortellini A, Pinato D, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Gallegos J, Trent J, Nusrat S, Malvar C, McKay R, Neilan T, Choueiri T, Naqash A. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. Journal For ImmunoTherapy Of Cancer 2025, 13: e009364. PMID: 40032601, PMCID: PMC11877189, DOI: 10.1136/jitc-2024-009364.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitor initiationImmune checkpoint inhibitorsTreatment-related adverse eventsObjective response rateProgression-free survivalCardiac metastasisOverall survivalRetrospective studyAnti-cytotoxic T-lymphocyte antigen 4Dose of immune checkpoint inhibitorsEfficacy of immune checkpoint therapyAnti-programmed death-1International multicenter retrospective studyMulticenter international retrospective studyT-lymphocyte antigen-4Non-small cell lung cancerMedian follow-up timeClinical outcomes of patientsICI-based regimensMultiple cardiac metastasesSolid Tumors V.1.1Immune checkpoint therapyResponse Evaluation CriteriaInternational retrospective studyMulticenter retrospective study
2024
Artificial Intelligence–Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases
Kuhn T, Engelhardt W, Kahl V, Alkukhun A, Gross M, Iseke S, Onofrey J, Covey A, Camacho J, Kawaguchi Y, Hasegawa K, Odisio B, Vauthey J, Antoch G, Chapiro J, Madoff D. Artificial Intelligence–Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases. Journal Of Vascular And Interventional Radiology 2024, 36: 477-488. PMID: 39638087, DOI: 10.1016/j.jvir.2024.11.025.Peer-Reviewed Original ResearchTotal liver volumeMetastatic colorectal cancer patientsPreoperative portal vein embolizationColorectal cancer liver metastasesPortal vein embolizationCancer liver metastasesMulticenter retrospective studyColorectal cancer patientsStudent's t-testBoard-certified radiologistsVein embolizationConsecutive patientsLiver metastasesLiver volumePatient selectionRetrospective studyCancer patientsRadiomic featuresInclusion criteriaPatientsSemi-automatic segmentationLab valuesT-testSDAUCHigh-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Evens A, Naik S, Kamdar M, Haverkos B, Karmali R, Farooq U, Vose J, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Advances 2024, 8: 5355-5364. PMID: 39189932, PMCID: PMC11568788, DOI: 10.1182/bloodadvances.2024013791.Peer-Reviewed Original ResearchBaseline CNS involvementCentral nervous system recurrenceHigh-grade B-cell lymphomaCentral nervous systemB-cell lymphomaCNS involvementCNS recurrenceIncidence of CNS recurrenceRisk of CNS recurrenceCentral nervous system involvementMulti-institutional seriesNon-GCB subtypeBone marrow involvementMulticenter retrospective studyCNS-IPIRisk factor analysisMarrow involvementMYC rearrangementNon-GCBPrimary therapyCD5 expressionAutologous transplantationSurvival outcomesNo significant differenceNOS patientsPersistent and newly developed gastrointestinal symptoms after surgery for intestinal malrotation in children: Dysmotility or disorders of gut and brain interaction?
Patel D, Banks D, Hira B, Ford M, Ambartsumyan L, Rodriguez L. Persistent and newly developed gastrointestinal symptoms after surgery for intestinal malrotation in children: Dysmotility or disorders of gut and brain interaction? Journal Of Pediatric Gastroenterology And Nutrition 2024, 78: 827-835. PMID: 38451033, DOI: 10.1002/jpn3.12178.Peer-Reviewed Original ResearchResolution of symptomsIntestinal malrotationGI symptomsFollow-upIncidental diagnosisPersistent gastrointestinal (GIPresence of postoperative symptomsPediatric tertiary care centerLong-term outcome of childrenMedian follow-upFactors associated with lackMulticenter retrospective studyPostoperative follow-upTertiary care centerAge of diagnosisTime to diagnosisLong-term outcomesRome IV criteriaGastrointestinal (GIOutcomes of childrenIdiopathic diagnosisOutcome variablesAssociated with disordersAssociation of demographicsClinical presentationClinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers
Abaza Y, Winer E, Murthy S, Shallis R, Matthews A, Badar T, Geramita E, Kota V, Swaroop A, Doukas P, Bradshaw D, Helenowski I, Liu Y, Zhang H, Im A, Litzow M, Perl A, Atallah E, Altman J. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers. American Journal Of Hematology 2024, 99: 606-614. PMID: 38342997, DOI: 10.1002/ajh.27231.Peer-Reviewed Original ResearchAcute myeloid leukemiaHypomethylating agentsOverall survivalElderly patientsMedian OSMyeloid leukemiaTP53-mutated acute myeloid leukemiaNewly diagnosed acute myeloid leukemiaFailure of hypomethylating agentsMedian duration of responseDiagnosed AMLVIALE-A trialMedian overall survivalIncomplete count recoveryDuration of responseMulticenter retrospective studySingle-center studyTreatment of patientsStandard of careCR/CRi rateIntensive chemotherapyCount recoveryMedian durationFrontline treatmentRetrospective studyClinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas A Multicenter Retrospective Study
Nassar A, El-Am E, Denu R, Alaiwi S, Zarif T, Macaron W, Abdel-Wahab N, Desai A, Smith C, Parikh K, Abbasi M, Farhat E, Williams J, Collins J, Al-Hader A, McKay R, Malvar C, Sabra M, Zhong C, Alam R, Chehab O, Lima J, Phan M, Pria H, Trevino A, Neilan T, Kwan J, Ravi V, Deshpande H, Demetri G, Choueiri T, Naqash A. Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas A Multicenter Retrospective Study. JACC CardioOncology 2024, 6: 71-79. PMID: 38510282, PMCID: PMC10950431, DOI: 10.1016/j.jaccao.2023.11.007.Peer-Reviewed Original ResearchMedian progression-free survivalProgression-free survivalImmune checkpoint inhibitorsSoft tissue sarcomasOverall survivalMedian OSTissue sarcomasClinical outcomesCommon Terminology Criteria for Adverse Events versionTreatment-related adverse eventsClinical outcomes of patientsMulti-institutional cohort studyResponse rateICI-based regimensObjective response rateSolid Tumors versionAdverse Events versionLocally advanced diseaseResponse Evaluation CriteriaImmunotherapy-treated patientsSecond-line therapyEstimate overall survivalFirst-line therapyMulticenter retrospective studyKaplan-Meier method
2023
Outcomes of cold snare EMR of nonampullary duodenal adenomas ≥1 cm: a multicenter study
Wilson N, Abdallah M, Schulman A, Mosko J, Saeed A, Kothari S, Kaul V, Kothari T, Phan J, Kumar A, Tofani C, Kim R, Westanmo A, Moy B, Dang F, Canakis A, Sharma N, Muniraj T, Azeem N, Bilal M. Outcomes of cold snare EMR of nonampullary duodenal adenomas ≥1 cm: a multicenter study. Gastrointestinal Endoscopy 2023, 99: 971-980.e1. PMID: 38092125, DOI: 10.1016/j.gie.2023.12.007.Peer-Reviewed Original ResearchNonampullary duodenal adenomasEndoscopic mucosal resectionCold snare endoscopic mucosal resectionSnare endoscopic mucosal resectionDuodenal adenomasUse of electrocauteryAdverse eventsMucosal resectionMulticenter studyUnderwater endoscopic mucosal resectionLarge duodenal adenomasMulticenter retrospective studyRetrospective multicenter studyPredictors of recurrenceAcceptable recurrence rateHigh-grade dysplasiaFuture prospective studiesCases of perforationAdenoma rateSecondary outcomesImmediate bleedingPrimary outcomeRecurrent adenomasIndependent predictorsProspective studyCharacteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study
Abaza Y, Xie Z, Burkart M, Badar T, Desai P, Shallis R, Patel A, Cohen-Nowak A, Oh T, Walker C, Easwar N, Kewan T, Cannova J, Bell-Burdett K, Al Ali N, Sallman D, Roboz G, Carraway H, Zeidan A, Patnaik M, Altman J, Komrokji R. Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study. Blood 2023, 142: 3232. DOI: 10.1182/blood-2023-188328.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeMedian overall survivalMulticenter retrospective studyRisk myelodysplastic syndromesOverall survivalYA groupMyelodysplastic syndromeYounger ptsComplete remissionAllo-SCTBaseline characteristicsFrontline therapyHematologic improvementMedian ageRetrospective studyCommon subtypeBlasts-2Exact testUpfront allogeneic stem cell transplantationIntermediate-risk myelodysplastic syndromesTherapy-related myelodysplastic syndromeAllogeneic stem cell transplantationDe novo myelodysplastic syndromeExcess blasts-2Marrow complete remissionImproved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy
Desai S, Sumransub N, Evans R, Watkins M, Karmali R, Goyal G, Hughes M, Khurana A, Hernandez-Ilizaliturri F, Zurko J, Hassan A, Hatic H, Nizamuddin I, Evens A, Anampa-Guzmán A, Lin Y, Isufi I, Hamadani M, Rajguru S, Lall N, Tun A, Hill B, Stephens D, Caimi P, Ermann D, Kahl B, Landsburg D, Nowakowski G. Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy. Blood 2023, 142: 308. DOI: 10.1182/blood-2023-183001.Peer-Reviewed Original ResearchHigh-grade B-cell lymphomaCART-cell therapyProgression-free survivalOverall survivalInferior overall survivalB-cell lymphomaCART cellsCell therapyRetrospective studyEra cohortCell lymphomaBCL6 rearrangementsLarge B-cell lymphomaAnthracycline-based therapySuperior overall survivalMulticenter retrospective studyHigher overall survivalElectronic health recordsAdult ptsPrior chemotherapyYr OSB symptomsBulky diseaseCART eraElevated LDHA multicenter retrospective study of patients treated in the thalamus with responsive neurostimulation
Fields M, Eka O, Schreckinger C, Dugan P, Asaad W, Blum A, Bullinger K, Willie J, Burdette D, Anderson C, Quraishi I, Gerrard J, Singh A, Lee K, Yoo J, Ghatan S, Panov F, Marcuse L. A multicenter retrospective study of patients treated in the thalamus with responsive neurostimulation. Frontiers In Neurology 2023, 14: 1202631. PMID: 37745648, PMCID: PMC10516547, DOI: 10.3389/fneur.2023.1202631.Peer-Reviewed Original ResearchAnterior thalamic nucleiSerious adverse eventsGlobal Clinical Impression ScaleVagal nerve stimulationDrug-resistant epilepsyDeep brain stimulationAdverse eventsMost patientsResponsive neurostimulationSeizure reductionResective surgeryResistant epilepsyImpression ScaleSide effectsMedian baseline seizure frequencyDrug-resistant epilepsy patientsRare serious adverse eventsAnti-seizure medicationsDifferent epilepsy centersMeaningful seizure reductionMedian seizure reductionMedication regimen changesBaseline seizure frequencyMulticenter retrospective studyRetrospective multicenter studyDirect Versus Indirect Revascularization for Moyamoya: a Large Multicenter Study
Naamani K, Chen C, Jabre R, Saad H, Grossberg J, Dmytriw A, Patel A, Khorasanizadeh M, Ogilvy C, Thomas A, Monteiro A, Siddiqui A, Cortez G, Hanel R, Porto G, Spiotta A, Piscopo A, Hasan D, Ghorbani M, Weinberg J, Nimjee S, Bekelis K, Salem M, Burkhardt J, Zetchi A, Matouk C, Howard B, Lai R, Du R, Abbas R, Sioutas G, Amllay A, Munoz A, Atallah E, Herial N, Tjoumakaris S, Gooch M, Rosenwasser R, Jabbour P. Direct Versus Indirect Revascularization for Moyamoya: a Large Multicenter Study. Journal Of Neurology Neurosurgery & Psychiatry 2023, 95: 256-263. PMID: 37673641, DOI: 10.1136/jnnp-2022-329176.Peer-Reviewed Original ResearchConceptsSymptomatic strokeChronic occlusive cerebrovascular diseaseIndirect revascularisationMulticenter retrospective studySurgical treatment modalitiesFollow-up strokeOcclusive cerebrovascular diseaseDR cohortIR cohortPatient risk assessmentModality of revascularizationLenticulostriate collateralsMulticenter studySurgical revascularizationCase seriesRetrospective studyRevascularization surgeryTreatment modalitiesIndirect revascularizationIR surgeryPerioperative strokeReporting of Observational StudiesRevascularization modalityRevascularizationEffective treatmentThe effect of occlusion location and technique in mechanical thrombectomy for minor stroke.
Abecassis I, Almallouhi E, Chalhoub R, Helal A, Naidugari J, Kasab S, Bass E, Ding D, Saini V, Burks J, Maier I, Jabbour P, Kim J, Wolfe S, Rai A, Psychogios M, Samaniego E, Arthur A, Yoshimura S, Howard B, Alawieh A, Fragata I, Cuellar H, Polifka A, Mascitelli J, Osbun J, Crosa R, Matouk C, Park M, Levitt M, Dumont T, Williamson R, Spiotta A, Starke R. The effect of occlusion location and technique in mechanical thrombectomy for minor stroke. Interventional Neuroradiology 2023, 15910199231196451. PMID: 37593806, DOI: 10.1177/15910199231196451.Peer-Reviewed Original ResearchNational Institutes of Health Stroke ScaleClinical outcomesDistal occlusionMechanical thrombectomySafety profileAssociated with good clinical outcomesAssociated with worse clinical outcomesAssociated with better clinical outcomesPatients treated with MTMulticenter retrospective studyNational Institutes of Health Stroke Scale scoreLarge vessel occlusion strokeModified Rankin ScaleDistal vessel occlusionEndovascular mechanical thrombectomyDistal occlusion groupComprehensive stroke centerHealth Stroke ScaleLocation of occlusionRetrospective studyOcclusion groupProcedure timeIV-tPAAtrial fibrillationEstablished treatmentPlatinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All “BRCAness” Is Created Equal
Doroshow D, Wei W, Mehrotra M, Sia D, Eder J, Bindra R, Houldsworth J, LoRusso P, Walther Z. Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All “BRCAness” Is Created Equal. Cancer Investigation 2023, 41: 646-655. PMID: 37505929, DOI: 10.1080/07357907.2023.2242957.Peer-Reviewed Original ResearchConceptsClinical benefit rateIntrahepatic cholangiocarcinomaPlatinum sensitivityUnresectable intrahepatic cholangiocarcinomaObjective response rateMulticenter retrospective studyHomologous recombination repairDefective homologous recombination (HR) repairPrimary endpointPlatinum chemotherapyRetrospective studyPreclinical dataBenefit rateWildtype tumorsResponse rateMT tumorsWT diseasePatientsGene defectsCholangiocarcinomaTumorsMonoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study
Sherman G, Lamb G, Sharma T, Lloyd E, Nagel J, Dandam N, Oliveira C, Sheikha H, Anosike B, Lee P, Vora S, Patel K, Sue P, Rubbab B, Yarbrough A, Ganapathi L, Nakamura M. Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study. Journal Of The Pediatric Infectious Diseases Society 2023, 12: 152-155. PMID: 36928172, PMCID: PMC10112679, DOI: 10.1093/jpids/piac124.Peer-Reviewed Original Research
2022
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Loo Gan C, Huang J, Pan E, Xie W, Schmidt A, Labaki C, Meza L, Bouchard G, Li H, Jackson-Spence F, Sánchez-Ruiz C, Powles T, Kumar S, Weise N, Hall W, Rose B, Beuselinck B, Suarez C, Pal S, Choueiri T, Heng D, McKay R. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology 2022, 6: 204-211. PMID: 36328934, DOI: 10.1016/j.euo.2022.10.004.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaMRCC treated with cabozantinibRenal cell carcinomaAdverse eventsRisk-benefit assessmentCell carcinomaReceiving radiotherapyInternational Metastatic Renal Cell Carcinoma Database ConsortiumPatients treated with stereotactic ablative body radiotherapyInternational multicenter retrospective studyStereotactic ablative body radiotherapyPractice patternsConventional palliative radiotherapyGrade 5 eventsIntermediate-risk diseaseReceipt of radiotherapyMultiple brain metastasesMetastatic kidney cancerRadiotherapy-related toxicityCourse of radiotherapyEfficacy of cabozantinibMulticenter retrospective studyStudy of patientsOptimize treatment outcomesAssessment of patientsNatural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study
Vandriel S, Li L, She H, Wang J, Gilbert M, Jankowska I, Czubkowski P, Gliwicz‐Miedzińska D, Gonzales E, Jacquemin E, Bouligand J, Spinner N, Loomes K, Piccoli D, D'Antiga L, Nicastro E, Sokal É, Demaret T, Ebel N, Feinstein J, Fawaz R, Nastasio S, Lacaille F, Debray D, Arnell H, Fischler B, Siew S, Stormon M, Karpen S, Romero R, Kim K, Baek W, Hardikar W, Shankar S, Roberts A, Evans H, Jensen M, Kavan M, Sundaram S, Chaidez A, Karthikeyan P, Sanchez M, Cavalieri M, Verkade H, Lee W, Squires J, Hajinicolaou C, Lertudomphonwanit C, Fischer R, Larson‐Nath C, Mozer‐Glassberg Y, Arikan C, Lin H, Bernabeu J, Alam S, Kelly D, Carvalho E, Ferreira C, Indolfi G, Quiros‐Tejeira R, Bulut P, Calvo P, Önal Z, Valentino P, Desai D, Eshun J, Rogalidou M, Dezsőfi A, Wiecek S, Nebbia G, Pinto R, Wolters V, Tamara M, Zizzo A, Garcia J, Schwarz K, Beretta M, Sandahl T, Jimenez‐Rivera C, Kerkar N, Brecelj J, Mujawar Q, Rock N, Busoms C, Karnsakul W, Lurz E, Santos‐Silva E, Blondet N, Bujanda L, Shah U, Thompson R, Hansen B, Kamath B, Group T. Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study. Hepatology 2022, 77: 512-529. PMID: 36036223, PMCID: PMC9869940, DOI: 10.1002/hep.32761.Peer-Reviewed Original ResearchConceptsNative liver survivalLarge international cohortAlagille syndromeInternational cohortNLS rateNative liverLiver diseaseMedian total bilirubin levelsEvent-free survival rateNatural historyEarly biochemical predictorsEvident portal hypertensionLiver-related eventsRisks of transplantationMulticenter retrospective studyTotal bilirubin levelsEvaluation of therapyMonths of ageGALA studyHepatic outcomesLiver survivalPortal hypertensionTertiary centerBilirubin levelsRetrospective studyThe Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting.
Riaz F, Zhu H, Cheng W, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Parikh R, Reuss J, Prsic E, Doroshow D. The Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.28_suppl.300.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsRetrospective studyInpatient settingOutcome studiesPT outcomesStage IV solid malignancyYale-New Haven HospitalImaging-based responseMedian prior linesNon-curative intentOutcome of ptsCTLA-4 inhibitorsMulticenter retrospective studyPD-L1 expressionPoor clinical outcomeCare of patientsTime of administrationMount Sinai HospitalGeorgetown University HospitalHealth care systemICI administrationICI doseICI initiationOutcome Prediction in Cerebral Venous Thrombosis: The IN-REvASC Score
Klein P, Shu L, Nguyen TN, Siegler JE, Omran SS, Simpkins AN, Heldner M, de Havenon A, Aparicio HJ, Abdalkader M, Psychogios M, Vedovati MC, Paciaroni M, von Martial R, Liebeskind DS, de Sousa D, Coutinho JM, Yaghi S, Group F. Outcome Prediction in Cerebral Venous Thrombosis: The IN-REvASC Score. Journal Of Stroke 2022, 24: 404-416. PMID: 36221944, PMCID: PMC9561213, DOI: 10.5853/jos.2022.01606.Peer-Reviewed Original ResearchCerebral venous thrombosisPoor neurological outcomePoor outcomeNeurological outcomeVenous thrombosisPrognostic scoreRisk factorsInternational multicenter retrospective studyMulticenter retrospective studyMultivariable logistic regressionFuture clinical trialsActive cancerHigher NIHSSConsecutive patientsMedian ageMultivariable analysisRetrospective studyMRS 3Black raceRadiographic characteristicsClinical trialsPrognostic accuracyHigh riskPatientsClinical decisionThe scope of treatment of pediatric IgA vasculitis nephritis and its outcome: a Pediatric Nephrology Research Consortium study
Kallash M, Vogt BA, Zeid A, Khin E, Najjar M, Aldughiem A, Benoit E, Stotter B, Rheault M, Warejko JK, Daga A. The scope of treatment of pediatric IgA vasculitis nephritis and its outcome: a Pediatric Nephrology Research Consortium study. Pediatric Nephrology 2022, 37: 2687-2697. PMID: 35233641, DOI: 10.1007/s00467-022-05496-3.Peer-Reviewed Original ResearchConceptsKidney biopsyGraphical abstractA higher resolution versionPediatric nephrology research consortium studyUrine protein/creatinine ratioProtein/creatinine ratioAnti-metabolite agentsIgA vasculitis nephritisPercent of patientsMulticenter retrospective studyChildren ages 1Scope of treatmentIgAV nephritisIS therapyKidney outcomesVasculitis nephritisNormal eGFRMicroscopic hematuriaOlder patientsCreatinine ratioMedian ageHeavy proteinuriaImmunosuppressive agentsKidney functionProspective studyRetrospective study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply